Scynexis Inc

NASDAQ:SCYX  
6.85
-0.10 (-1.44%)
Products, Regulatory

Scynexis Says 6-Month Priority Review Granted For Ibrexafungerp With Pdufa Target Action Date Set For June 1 2021

Published: 12/07/2020 13:35 GMT
Scynexis Inc (SCYX) - Scynexis Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections.
Scynexis Inc - 6-month Priority Reviewgranted for Ibrexafungerp With PDUFA Target Action Date Set Forjune 1, 2021.
Scynexis Inc - Co is Continuing Preparations for a U.S. Commercial Launch of Ibrexafungerp in 2nd Half 2021.
Scynexis Inc - FDA Indicated That It is Not Currently Planning to Hold an Advisory Committee Meeting for Application.